Low-profile access port

Information

  • Patent Grant
  • 10463845
  • Patent Number
    10,463,845
  • Date Filed
    Thursday, January 23, 2014
    10 years ago
  • Date Issued
    Tuesday, November 5, 2019
    4 years ago
Abstract
A low-profile access port for subcutaneous implantation within the body of a patient is disclosed. The access port includes a receiving cup that provides a relatively large subcutaneous target to enable a catheter-bearing needle to access the port without difficulty. In addition, the access port includes a valve/seal assembly to permit pressurized fluid injection through the port while preventing backflow. In one embodiment, therefore, a low-profile access port comprises a body including a conduit with an inlet port at a proximal end thereof, and a receiving cup. The receiving cup is concavely shaped to direct a catheter-bearing needle into the conduit via the inlet port. The receiving cup is oriented substantially toward a skin surface when subcutaneously implanted within the patient to ease needle impingement thereon. A valve/seal assembly disposed in the conduit enables passage of the catheter therethrough while preventing fluid backflow.
Description
BRIEF SUMMARY

Briefly summarized, embodiments of the present invention are directed to a low-profile access port for subcutaneous implantation within the body of a patient. The access port includes a receiving cup that provides a relatively large subcutaneous target to enable a catheter-bearing needle to access the port without difficulty. In addition, the access port includes a valve/seal assembly to permit pressurized fluid injection through the port while preventing backflow.


In one embodiment, therefore, a low-profile access port comprises a body including a conduit with an inlet port at a proximal end thereof, and a receiving cup. The receiving cup is concavely shaped to direct a catheter-bearing needle into the conduit via the inlet port. The receiving cup is oriented substantially toward a skin surface when subcutaneously implanted within the patient to ease needle impingement thereon. A valve/seal assembly disposed in the conduit enables passage of the catheter therethrough while preventing fluid backflow.


These and other features of embodiments of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of embodiments of the invention as set forth hereinafter.





BRIEF DESCRIPTION OF THE DRAWINGS

A more particular description of the present disclosure will be rendered by reference to specific embodiments thereof that are illustrated in the appended drawings. It is appreciated that these drawings depict only typical embodiments of the invention and are therefore not to be considered limiting of its scope. Example embodiments of the invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:



FIGS. 1A-1E show various views of an access port according to one embodiment;



FIG. 2 is a cross sectional view of the access port of FIGS. 1A-1E;



FIG. 3A-3C are various views of a low-profile access port according to one embodiment;



FIG. 4 is a top view of a low-profile access port according to one embodiment;



FIG. 5 is a perspective view of a low-profile access port according to one embodiment;



FIG. 6 is a perspective view of a low-profile access port according to one embodiment;



FIGS. 7A and 7B are various views of an access port according to one embodiment; and



FIGS. 8A and 8B are various views of an access port according to one embodiment.





DETAILED DESCRIPTION OF SELECTED EMBODIMENTS

Reference will now be made to figures wherein like structures will be provided with like reference designations. It is understood that the drawings are diagrammatic and schematic representations of exemplary embodiments of the present invention, and are neither limiting nor necessarily drawn to scale.


For clarity it is to be understood that the word “proximal” refers to a direction relatively closer to a clinician using the device to be described herein, while the word “distal” refers to a direction relatively further from the clinician. For example, the end of a catheter placed within the body of a patient is considered a distal end of the catheter, while the catheter end remaining outside the body is a proximal end of the catheter. Also, the words “including,” “has,” and “having,” as used herein, including the claims, shall have the same meaning as the word “comprising.”


Embodiments of the present invention are generally directed to an access port for subcutaneous implantation within the body of a patient. The implanted access port is transcutaneously accessible by a catheter-bearing needle, such as a peripheral intravenous (“PIV”) catheter, so as to place the PIV catheter into fluid communication with the access port. A fluid outlet of the access port is operably connected to an in-dwelling catheter disposed within the vasculature of a patient, in one embodiment, to enable the infusion into and/or removal of fluids from the patient's vasculature to take place via the PIV catheter.


In accordance with one embodiment, the access port defines a low profile so as to facilitate ease of placement within the subcutaneous tissue of the patient. Further, the access port is configured to provide a relatively large subcutaneous target to enable the PIV catheter or other suitable catheter-bearing needle to access the port without difficulty. In addition, the access port includes a valve/seal assembly to permit the injection of fluids through the access port at a relatively high flow rate, such as about 5 ml per second at a pressure of about 300 psi (also referred to herein as “power injection”). Possible applications for the access port described herein include administration of medicaments and other fluids to the patient, pheresis, fluid aspiration, etc.


Reference is first made to made to FIGS. 1A-1E, which show various details of an access port, generally designated at 10, in accordance with one embodiment. As shown, the port 10 includes a body 12 that is defined in the present embodiment by a first portion 12A and a second portion 12B (FIG. 1E). In the present embodiment the port body 12 includes a metal such as titanium, and as such, the second portion 12B is press fit into engagement with the first portion 12A to define the body, though it is appreciated that the port body can include a variety of other materials, including metals, thermoplastics, ceramics, etc.


The port body 12 defines in the present embodiment a substantially concavely-shaped receiving cup 14 for receiving and directing a catheter-bearing needle (FIG. 2) to operably connect with the port 10, as described further below. In particular, the substantially concave shape of the receiving cup 14 is configured to direct a catheter-bearing needle (FIG. 2) impinging thereon toward an inlet port 16 that serves as an opening for a conduit 18 defined by the port body 12. The open and shallow nature of the receiving cup 14 together with its substantially upward orientation (i.e., toward the skin surface of the patient), so that it is substantially parallel to the skin surface when subcutaneously implanted under the skin of the patient (i.e., the receiving cup is substantially parallel to the skin surface when the skin is at rest, or undeformed by digital pressure or manipulation), enables the receiving cup to present a large, easily accessible target for the needle when introduced into the skin, as seen in FIG. 2. FIG. 2 further shows that the port 10 defines a relatively low profile height, which enables relatively shorter needle lengths to be used for accessing the port after implantation.


Palpation features 26 are included with the port body 12 to assist a clinician to locate and/or identify the port 10 via finger palpation after implantation under the skin of the patient. In detail, the palpation features 26 in the present embodiment include a bump 26A disposed near the proximal end of the receiving cup 14 and a ridge 26B disposed above and curving around a distal portion of the receiving cup. FIG. 1B shows that the palpation features extend above the general upper plane defined by the port 10 so as to facilitate palpation of the features by a clinician in order to locate the position and/or orientation of the receiving cup 14. Note that a variety of other sizes, configurations, numbers, etc., of palpation features can be included on the port in addition to what is shown and described herein.


A guide groove 28 is defined on the receiving cup 14 and is longitudinally aligned with the inlet port 16 of the conduit 18. The guide groove 28 is defined as a depression with respect to adjacent portions of the surface of the receiving cup 14 and extends distally along the receiving cup surface from a proximal portion of the receiving cup so as to provide a guide path to guide the distal tip of the catheter-bearing needle toward the inlet port 16 once impingement of the needle into the guide groove is made. This in turn reduces the chance the needle will slide across and off the receiving cup 14 during insertion. Note that these and other similar features, though differing in shape and configuration, can also be included on the other ports disclosed herein.


As best seen in FIG. 1E, the port body 12 further defines the conduit 18 as a pathway into which a transcutaneously inserted catheter can pass so as to place the catheter in fluid communication with the port 10. As shown, the conduit 18 is in communication with the receiving cup 14 via the inlet port 16. A first conduit portion 18A of the conduit 18 distally extends from the inlet port 16 in an angled downward direction from the perspective shown in FIG. 1E to a bend 30, where a second conduit portion 18B of the conduit angles slightly upward and changes direction at a predetermined angle θ1. Note that angle orientation θ1 in one embodiment is about 37 degrees, but can vary from this in other embodiments, including angles less than 37 degrees in one embodiment. The magnitude of angle θ1 depends in one embodiment on various factors, including the size of the catheter and/or needle to be inserted into the port conduit, the size of the conduit itself, etc.


The conduit 18 then extends to and through a cavity 20A defined by a valve housing 20 of the port body. The conduit 18 extends to a distal open end of the stem 24 of the port 10. The conduit 18 is sized so as to enable the catheter 40 (FIG. 2) to pass therethrough, as will be seen.


As mentioned, the valve housing 20 defines a cavity 20A through which the conduit passes and which houses a valve/seal assembly 22. The valve/seal assembly 22 includes a sealing element, or seal 32, which defines a central hole through which the catheter 40 can pass, a first slit valve 34A and a second slit valve 34B. The seal 32 and valves 34A, 34B are sandwiched together in one embodiment and secured in place within the cavity 20A as shown in FIG. 1E. The slits of the slit valves 34A, 34B are rotationally offset from one another by about 90 degrees in the present embodiment, though other relationships are possible.


The seal 32 and valves 34A, 34B of the valve/seal assembly 22 cooperate to enable fluid-tight passage therethrough of the catheter 40 (FIG. 2) while also preventing backflow of fluid through the valve/seal assembly. Indeed, in one embodiment the seals disclosed herein prevent fluid flow around the external portion of the catheter when the catheter is disposed through the seal, while the valves are suitable for preventing fluid flow when no catheter passes through them. As such, when the catheter 40 is not inserted therethrough the valve/seal assembly 22 seals to prevent passage of air or fluid. In the present embodiment, the seal 32 and valves 34A, 34B include silicone, though other suitably compliant materials can be employed.


The port 10 in the present embodiment includes an overmolded portion 36 that covers the port body 12. The overmolded portion 36 includes silicone or other suitably compliant material and surrounds the body 12 as shown so as to provide a relatively soft surface for the port 10 and reduce patient discomfort after port implantation. The overmolded portion 36 includes two predetermined suture locations 38, best seen in FIG. 1C, for suturing the port 10 to patient tissue, though sutures may be passed through other portions of the overmolded portion, if desired. The overmolded portion 36 further defines a relatively flat bottom surface 36A so as to provide a stable surface for the port 10 in its position within the tissue pocket after implantation. In contrast, the port shown in FIG. 3C includes a bottom surface with a slightly rounded profile.



FIG. 2 depicts details regarding the insertion of the catheter 40 disposed on the needle 42, according to one embodiment. After locating the port 10 via through-skin palpation of the palpation features 26, a clinician uses the catheter-bearing needle 42 to pierce a skin surface 44 and insert the needle until a distal tip 42A thereof impinges on a portion of the receiving cup 14, as shown. Note that, because of the orientation of the receiving cup 14 as substantially parallel to the skin surface, the needle 42 can impinge on the receiving cup at an insertion angle θ2 that is relatively steep, which facilitates ease of needle insertion into the body. Indeed, in one embodiment a needle inserted substantially orthogonally through the skin of the patient can impinge the receiving cup of the access port.


The needle 42 is manipulated until the distal tip 42A is received into the guide groove 28, which will enable the distal tip to be guided along the groove to the inlet port 16. The needle 42 is then inserted through the inlet port 16 and into the first portion 18A of the conduit 18 until it is stopped by the bend 30. The needle 42 can then be proximally backed out a small distance, and the catheter 40 advanced over the needle such that the catheter bends and advances past the bend 30 into the second portion 18B of the conduit 18. Catheter advancement continues such that a distal end 40A of the catheter 40 advances into and past the hole of the seal 32 and through both slits of the slit valves 34A, 34B of the valve/seal assembly 40. Once the distal end 40A of the catheter 40 has extended distally past the valve/seal assembly 22, further advancement can cease and fluid transfer through the catheter 40 and port 10 can commence, including infusion and/or aspiration through the stem 24. Once fluid transfer is completed, the catheter 40 can be withdrawn proximally through the valve/seal assembly 22 and the conduit, then withdrawn through the surface 44 of the skin and out of the patient.



FIGS. 3A-3C depict details of an access port 110 according to another embodiment. Note that various similarities exist between the port 10 and the other ports shown and described herein. As such, only selected port aspects are discussed below. As shown, the port 110 includes a body 112 that in turn includes a first body portion 112A and a second body portion 112B, best seen in FIG. 3C. The body 112 in the present embodiment includes a thermoplastic, such as an acetyl resin in the present embodiment. As such, the first and second body portions 112A, 112B are ultrasonically welded to one another to define the body 12, in the present embodiment. As before, a receiving cup 114 is included with the body 112 and is operably connected to a conduit 118 via an inlet port 116. Also, note that a variety of materials can be used to define the port body, receiving cup, conduit, etc.


A valve/seal assembly 122 is disposed within a cavity 120A that is defined by a valve housing 120, which in the present embodiment, is defined by the first body portion 112A. The valve/seal assembly 122 includes a proximal seal 132 with a central hole for catheter passage, two slit valves 134A, 134B each with a slit arranged at a 90-degree offset with respect to the other, and a distal seal 135 with a central hole, also referred to herein as a sphincter seal.


The distal seal 135 includes on its distal surface a frustoconical portion 135A disposed about the seal central hole that is configured to provide a sphincter-like seal about the outer surface of a catheter when it extends through the valve/seal assembly. The frustoconical portion 135A is disposed such that any back-flowing fluid impinging on the frustoconical portion will cause the seal to secure itself about the outer surface of the catheter in an even tighter engagement, thus preventing backflow past the catheter outer surface when high fluid pressures are present, such as in the case of power injection. As mentioned, other valve/seal combinations can also be included in the valve/seal assembly.


In the present embodiment, the receiving cup 114 and portion of the conduit 118 proximal to the valve/seal assembly 122 both include a needle-impenetrable lining that prevents the distal end of a needle from gouging the surface when impinging thereon. This, in turn, prevents the undesirable creation of material flecks dug by the needle. Various suitable materials can be employed for the needle-impenetrable material, including glass, ceramic, metals, etc. In one embodiment, the components of the port 110 are all non-metallic such that the port is considered MRI-safe, by which the port does not produce undesired artifacts in MRI images taken of the patient when the port is in implanted therewithin.



FIG. 4 depicts additional features of the port 110 according to another embodiment. As shown, in the present embodiment the receiving cup 18 includes radiopaque indicia 128 to indicate a characteristic of the port 110. Here, the radiopaque indicia 128 includes a “C” and a “T” that are formed by a radiopaque material, such as tungsten, bismuth trioxide, etc., so as to be visible after port implantation via x-ray imaging technology. For instance, the radiopaque material can be formed as an insert that is insert-molded included in the port body, as an initially flowable material that is injected into a cavity of the port body before hardening, etc. In embodiments where the port body is metallic, the radiopaque indicia can be formed by etching, engraving, or otherwise producing a relative thickness difference between the indicia and the surrounding port body material so as to produce an x-ray-discernible contrast that shows up in an x-ray image.


In the present embodiment, the CT radiopaque indicia 128 indicate to an observer that the port is capable of power injection of fluids therethrough. In addition to this characteristic, other characteristics can be indicated by various other types of indicia as appreciated by one skilled in the art.


Further, in the present embodiment the top view of the port 110 of FIG. 4 indicates that the port body 112 in the region surrounding the receiving cup 114 defines a generally triangular shape, which can be palpated by a clinician after implantation and can indicate not only the location of the receiving cup, but also a particular characteristic of the port, such as its ability to be used for power injection. Of course, the receiving cup may define shapes other than triangular in other embodiments.



FIG. 4 further shows that distributed about the perimeter of the receiving cup 114 are three palpation features 126, namely, three suture plugs 126A disposed in corresponding holes defined in the port body 112. The suture plugs 126A include raised silicone bumps in the present embodiment and can serve to locate the position of the receiving cup 114 post-implantation when they are palpated by a clinician prior to needle insertion into the patient. Various other palpation features could be included with the port, in other embodiments.



FIG. 5 depicts details of a low-profile port 210 according to one embodiment, including a body 212 defining a concavely-shaped receiving cup 214 and an inlet port 216 positioned slightly off-center with respect to the receiving cup. A stem 224 is included as a fluid outlet.



FIG. 6 depicts the low-profile port 210 according to another embodiment, wherein the body 212 defining additional surface features, including a raised palpation feature 226 distal to the receiving cup 214. In light of FIGS. 5 and 6, it is thus appreciated that the port can be configured in a variety of shapes and configurations to provide a low-profile solution for providing vascular access. Note also that the receiving cup shape, design, and configuration can vary from is explicitly shown and described herein.



FIGS. 7A and 7B depict various details of a low-profile dual-body access port 310 according to one embodiment, wherein each of the port bodies 312 defines a receiving cup 314 that is laterally facing and includes an inlet port 316 leading to a conduit 318. The conduit 318 extends distally to a valve/seal assembly 322 disposed in a valve housing 320, which in the present embodiment, is defined by a portion of the body 312. The conduit 318 extends through the port 324. A compliant overmolded portion 324 covers portions of each body 312 of the port 310 and operably joins the bodies to one another. The bodies 312 can include any suitable material, including metal, thermoplastic, etc.



FIGS. 8A and 8B depict various details of a low-profile dual-body access port 410 according to one embodiment, wherein a port body 412 defines dual fluid paths. Each fluid path includes a receiving cup 414 defined by the body 412 and facing a substantially upward orientation from the perspective shown in FIGS. 8A and 8B. An inlet port 416 is included with each receiving cup 414 and defines the opening to a conduit 418. Each conduit 418 extends distally to a valve/seal assembly 422 disposed in a valve housing 420, which in the present embodiment, is defined by a portion of the body 412. The conduit 418 extends through the port 424. The body 412 can include any suitable material, including metal, thermoplastic, etc.


Embodiments of the invention may be embodied in other specific forms without departing from the spirit of the present disclosure. The described embodiments are to be considered in all respects only as illustrative, not restrictive. The scope of the embodiments is, therefore, indicated by the appended claims rather than by the foregoing description. All changes that come within the meaning and range of equivalency of the claims are to be embraced within their scope.

Claims
  • 1. A low-profile access port for subcutaneous placement in a patient, comprising: a body including: a conduit;a receiving cup including: a concavely shaped surface having a length greater than a width;an upper opening lying in an upper plane;a lower opening in communication with the conduit; anda single guide groove defining a depression in the concavely shaped surface along the length from a proximal portion of the receiving cup to the lower opening to redirect an impinging distal tip of a needle into the conduit via the lower opening; anda palpation bump positioned at a proximal end of the receiving cup, the palpation bump extending through the upper plane; anda valve/seal assembly disposed in the conduit that enables passage of a catheter therethrough.
  • 2. The access port as defined in claim 1, wherein the conduit includes a first conduit portion and a second conduit portion, the second conduit portion positioned distal to and at an angled orientation with respect to the first conduit portion.
  • 3. The access port as defined in claim 2, wherein the second conduit portion is disposed at an angle less than about 37 degrees with respect to the first conduit portion.
  • 4. The access port as defined in claim 1, wherein the upper plane is positioned substantially parallel to a skin surface when the access port is subcutaneously implanted.
  • 5. The access port as defined in claim 1, wherein the conduit includes a first portion in communication with the lower opening and a second portion in communication with the first portion, wherein the first portion is angled toward a bottom surface of the access port, and wherein the second portion is angled toward a top surface of the access port.
  • 6. The access port as defined in claim 1, further comprising a stem having a proximal portion positioned within a distal cavity of the body, the proximal portion of the stem including an inlet in communication with the valve/seal assembly.
  • 7. The access port as defined in claim 1, further comprising a palpation ridge disposed opposite the palpation bump on the receiving cup.
  • 8. The access port as defined in claim 7, wherein the palpation ridge extends over the upper opening and the lower opening of the receiving cup.
  • 9. The access port as defined in claim 1, further comprising a housing surrounding the body, the housing forming a top surface and a bottom surface of the access port.
  • 10. The access port as defined in claim 9, wherein the bottom surface is flat, and wherein the bottom surface is parallel to the top surface.
  • 11. The access port as defined in claim 1, wherein the valve/seal assembly includes a first seal, a first slit valve, and a second slit valve positioned in a sandwiched configuration with respect to one another.
  • 12. The access port as defined in claim 1, wherein at least a portion of the receiving cup includes a needle-impenetrable material.
  • 13. The access port as defined in claim 12, wherein the needle-impenetrable material includes at least one of metal, glass, and ceramic.
  • 14. The access port as defined in claim 1, wherein the body includes at least one of a metal and a thermoplastic.
  • 15. The access port as defined in claim 14, wherein at least a portion of the body includes at least one of titanium and acetyl resin.
  • 16. The access port as defined in claim 15, wherein the palpation bump includes a portion on the concavely shaped surface proximal of the guide groove that is substantially centered in the receiving cup.
  • 17. A method for manufacturing a low-profile access port for subcutaneous placement in a patient, the method comprising: providing a body defining a conduit, the body including: a receiving cup defining an upper opening and a concavely shaped surface, the upper opening lying in an upper plane, the receiving cup including: a lower opening in communication with the conduit; anda single guide groove defining a depression in the concavely shaped surface to direct an impinging distal tip of a catheter-bearing needle into the conduit via the lower opening; anda distal cavity in communication with the conduit;overmolding a silicone housing around the body to form a top surface and a bottom surface of the low-profile access port, wherein the bottom surface is parallel to the upper plane;placing a valve/seal assembly in the distal cavity; andinserting a proximal end of a stem into the distal cavity to capture the valve/seal assembly in the body between the conduit and the stem.
  • 18. A low-profile access port for subcutaneous placement in a patient, comprising: a body including: a conduit;a receiving cup including: a concavely shaped surface having a length greater than a width;an upper opening lying in an upper plane;a lower opening in communication with the conduit; anda guide groove defining a depression in the concavely shaped surface along the length from a proximal portion of the receiving cup to the lower opening to guide a distal tip of a needle toward the lower opening; anda palpation bump positioned at a proximal end of the receiving cup, the palpation bump extending above the upper plane; anda valve/seal assembly in communication with the conduit that enables passage of a catheter therethrough, and including at least one seal for preventing backflow through the valve/seal assembly.
  • 19. The access port as defined in claim 18, further comprising a palpation ridge disposed opposite the palpation bump on the receiving cup.
  • 20. The access port as defined in claim 19, wherein the at least one seal defines a central hole therethrough and wherein a distal face of the at least one seal includes a frustoconical portion disposed about the central hole for preventing backflow past the catheter when fluid is passed through the catheter under pressure.
  • 21. The access port as defined in claim 20, wherein the upper plane is oriented substantially toward a skin surface when subcutaneously implanted within the patient, and wherein a compliant overmolded portion surrounds the body of the access port.
  • 22. The access port as defined in claim 21, wherein the overmolded portion includes at least one predetermined region through which sutures can be passed to secure the access port to tissue of the patient.
  • 23. The access port as defined in claim 22, wherein the valve/seal assembly further includes first and second slit valves that are sandwiched between the at least one seal and a second seal.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application No. 61/755,913, filed Jan. 23, 2013, and titled “Low Profile Access Port,” which is incorporated herein by reference in its entirety.

US Referenced Citations (331)
Number Name Date Kind
3951147 Tucker et al. Apr 1976 A
4184489 Burd Jan 1980 A
4222374 Sampson et al. Sep 1980 A
4400169 Stephen Aug 1983 A
4447237 Frisch et al. May 1984 A
4496349 Cosentino Jan 1985 A
4543088 Bootman et al. Sep 1985 A
4559039 Ash et al. Dec 1985 A
4569675 Prosl et al. Feb 1986 A
4673394 Fenton, Jr. et al. Jun 1987 A
4692146 Hilger Sep 1987 A
4695273 Brown Sep 1987 A
4704103 Stober et al. Nov 1987 A
4710174 Moden et al. Dec 1987 A
4762517 McIntyre et al. Aug 1988 A
4767410 Moden et al. Aug 1988 A
4772270 Wiita et al. Sep 1988 A
4772276 Wiita et al. Sep 1988 A
4778452 Moden et al. Oct 1988 A
4790826 Elftman Dec 1988 A
4802885 Weeks et al. Feb 1989 A
4804054 Howson et al. Feb 1989 A
4820273 Reinicke Apr 1989 A
4861341 Woodburn Aug 1989 A
4886501 Johnston et al. Dec 1989 A
4892518 Cupp et al. Jan 1990 A
4897081 Poirier et al. Jan 1990 A
4904241 Bark Feb 1990 A
4915690 Cone et al. Apr 1990 A
4929236 Sampson May 1990 A
4963133 Whipple Oct 1990 A
4978338 Melsky et al. Dec 1990 A
5013298 Moden et al. May 1991 A
5041098 Loiterman et al. Aug 1991 A
5045060 Melsky et al. Sep 1991 A
5045064 Idriss Sep 1991 A
5053013 Ensminger et al. Oct 1991 A
5057084 Ensminger et al. Oct 1991 A
5084015 Moriuchi Jan 1992 A
5090954 Geary Feb 1992 A
5108377 Cone et al. Apr 1992 A
5137529 Watson et al. Aug 1992 A
5147321 Slonina et al. Sep 1992 A
5147483 Melsky et al. Sep 1992 A
5158547 Doan et al. Oct 1992 A
5167633 Mann et al. Dec 1992 A
5167638 Felix et al. Dec 1992 A
5171228 McDonald Dec 1992 A
5178612 Fenton, Jr. Jan 1993 A
5180365 Ensminger et al. Jan 1993 A
5185003 Brethauer Feb 1993 A
5201715 Masters Apr 1993 A
5203771 Melker et al. Apr 1993 A
5213574 Tucker May 1993 A
D337637 Tucker Jul 1993 S
5226879 Ensminger et al. Jul 1993 A
5263930 Ensminger Nov 1993 A
5266071 Elftman Nov 1993 A
5281199 Ensminger et al. Jan 1994 A
5281205 McPherson Jan 1994 A
5318545 Tucker Jun 1994 A
5336194 Polaschegg et al. Aug 1994 A
5350360 Ensminger et al. Sep 1994 A
5356381 Ensminger Oct 1994 A
5360407 Leonard et al. Nov 1994 A
5387192 Glantz et al. Feb 1995 A
5395324 Hinrichs et al. Mar 1995 A
5399168 Wadsworth, Jr. et al. Mar 1995 A
5405325 Labs Apr 1995 A
5417656 Ensminger et al. May 1995 A
5421814 Geary Jun 1995 A
5423334 Jordan Jun 1995 A
5476451 Ensminger et al. Dec 1995 A
5503630 Ensminger et al. Apr 1996 A
5514103 Srisathapat et al. May 1996 A
5520643 Ensminger et al. May 1996 A
5527277 Ensminger et al. Jun 1996 A
5527278 Ensminger et al. Jun 1996 A
5531684 Ensminger et al. Jul 1996 A
5542923 Ensminger et al. Aug 1996 A
5554117 Ensminger et al. Sep 1996 A
5556381 Ensminger et al. Sep 1996 A
5558641 Glantz et al. Sep 1996 A
5562617 Finch, Jr. et al. Oct 1996 A
5562618 Cai et al. Oct 1996 A
5575770 Melsky et al. Nov 1996 A
5578070 Utterberg Nov 1996 A
5607393 Ensminger et al. Mar 1997 A
5613945 Cai et al. Mar 1997 A
5620419 Lui et al. Apr 1997 A
5632729 Cai et al. May 1997 A
5647855 Trooskin Jul 1997 A
5695490 Flaherty et al. Dec 1997 A
5702363 Flaherty Dec 1997 A
5713858 Heruth et al. Feb 1998 A
5718682 Tucker Feb 1998 A
5725507 Petrick Mar 1998 A
5741228 Lambrecht Apr 1998 A
5743873 Cai et al. Apr 1998 A
5758667 Slettenmark Jun 1998 A
5769823 Otto Jun 1998 A
5792104 Speckman Aug 1998 A
5810789 Powers et al. Sep 1998 A
5833654 Powers et al. Nov 1998 A
5848989 Villani Dec 1998 A
5906596 Tallarida May 1999 A
5908414 Otto et al. Jun 1999 A
5913998 Butler et al. Jun 1999 A
5925017 Kriesel et al. Jul 1999 A
5931829 Burbank et al. Aug 1999 A
5944688 Lois Aug 1999 A
5947953 Ash et al. Sep 1999 A
5951512 Dalton Sep 1999 A
5954687 Baudino Sep 1999 A
5954691 Prosl Sep 1999 A
5968011 Larsen et al. Oct 1999 A
5989206 Prosl et al. Nov 1999 A
5989216 Johnson et al. Nov 1999 A
5989239 Finch et al. Nov 1999 A
6007516 Burbank et al. Dec 1999 A
6013051 Nelson Jan 2000 A
6013058 Prosl et al. Jan 2000 A
6022335 Ramadan Feb 2000 A
6039712 Fogarty et al. Mar 2000 A
6042569 Finch, Jr. et al. Mar 2000 A
6053901 Finch, Jr. et al. Apr 2000 A
6056717 Finch et al. May 2000 A
6086555 Eliasen et al. Jul 2000 A
6090067 Carter Jul 2000 A
6090068 Chanut Jul 2000 A
6102884 Squitieri Aug 2000 A
6120492 Finch et al. Sep 2000 A
6190349 Ash et al. Feb 2001 B1
6190352 Haarala et al. Feb 2001 B1
6206851 Prosl Mar 2001 B1
6213973 Eliasen et al. Apr 2001 B1
D445175 Bertheas Jul 2001 S
6287293 Jones et al. Sep 2001 B1
6332874 Eliasen et al. Dec 2001 B1
6350251 Prosl et al. Feb 2002 B1
6352521 Prosl Mar 2002 B1
6398764 Finch, Jr. et al. Jun 2002 B1
6436084 Finch et al. Aug 2002 B1
6438397 Bosquet et al. Aug 2002 B1
6459917 Gowda et al. Oct 2002 B1
6478783 Moorehead Nov 2002 B1
6482197 Finch et al. Nov 2002 B2
6494867 Elver et al. Dec 2002 B1
6506182 Estabrook et al. Jan 2003 B2
6527754 Tallarida et al. Mar 2003 B1
6540717 Sherry Apr 2003 B2
6582409 Squitieri Jun 2003 B1
6607504 Haarala et al. Aug 2003 B2
6620118 Prosl et al. Sep 2003 B1
6695832 Schon et al. Feb 2004 B2
6699218 Flaherty et al. Mar 2004 B2
6719749 Schweikert et al. Apr 2004 B1
6726711 Langenbach et al. Apr 2004 B1
6758841 Haarala et al. Jul 2004 B2
6783522 Fischell Aug 2004 B2
6852106 Watson et al. Feb 2005 B2
6881211 Schweikert et al. Apr 2005 B2
6929631 Brugger et al. Aug 2005 B1
6960185 Adaniya et al. Nov 2005 B2
6962580 Adams et al. Nov 2005 B2
6997914 Smith et al. Feb 2006 B2
7018374 Schon et al. Mar 2006 B2
7056316 Burbank et al. Jun 2006 B1
7070591 Adams et al. Jul 2006 B2
7083648 Yu et al. Aug 2006 B2
7108686 Burke et al. Sep 2006 B2
7131962 Estabrook Nov 2006 B1
7223257 Shubayev et al. May 2007 B2
7261705 Edoga et al. Aug 2007 B2
7311702 Tallarida et al. Dec 2007 B2
7322953 Redinger Jan 2008 B2
D562443 Zinn et al. Feb 2008 S
7347843 Adams et al. Mar 2008 B2
7351233 Parks Apr 2008 B2
7396359 Derowe et al. Jul 2008 B1
D574950 Zawacki et al. Aug 2008 S
D578203 Bizup Oct 2008 S
7445614 Bunodiere et al. Nov 2008 B2
D582032 Bizup et al. Dec 2008 S
7497850 Halili Mar 2009 B2
D612479 Zawacki et al. Mar 2010 S
7699821 Nowak Apr 2010 B2
7704225 Kantrowitz Apr 2010 B2
7708722 Glenn May 2010 B2
7713251 Tallarida et al. May 2010 B2
7731680 Patton Jun 2010 B2
7762999 Byrum Jul 2010 B2
7824365 Haarala et al. Nov 2010 B2
7846139 Zinn et al. Dec 2010 B2
7850666 Schon et al. Dec 2010 B2
7909804 Stats Mar 2011 B2
7959615 Stats et al. Jun 2011 B2
7972315 Birk et al. Jul 2011 B2
7981094 Chelak Jul 2011 B2
D650475 Smith et al. Dec 2011 S
8075536 Gray et al. Dec 2011 B2
8079990 Powley et al. Dec 2011 B2
8147455 Butts et al. Apr 2012 B2
8152792 Komel Apr 2012 B1
8257325 Schweikert et al. Sep 2012 B2
8277425 Girard et al. Oct 2012 B2
8328768 Quigley et al. Dec 2012 B2
8337464 Young et al. Dec 2012 B2
8337465 Young et al. Dec 2012 B2
8337470 Prasad et al. Dec 2012 B2
8343108 Rosenberg et al. Jan 2013 B2
8364230 Simpson et al. Jan 2013 B2
8377034 Tallarida et al. Feb 2013 B2
8425416 Brister et al. Apr 2013 B2
8425476 Glenn Apr 2013 B2
8480560 Vendely Jul 2013 B2
8550981 Woodruff et al. Oct 2013 B2
8574204 Boume et al. Nov 2013 B2
RE44639 Squitieri Dec 2013 E
8622980 Zinn Jan 2014 B2
8690815 Porter et al. Apr 2014 B2
8690816 Dakin et al. Apr 2014 B2
8738151 Nelson May 2014 B2
8979806 Saab Mar 2015 B2
9033931 Young May 2015 B2
9061129 Lauer Jun 2015 B2
9072880 Phillips et al. Jul 2015 B2
9072881 Dalton et al. Jul 2015 B2
9078982 Lane et al. Jul 2015 B2
9089395 Honaryar Jul 2015 B2
9095665 Pages et al. Aug 2015 B2
9138563 Glenn Sep 2015 B2
9168365 Bourne et al. Oct 2015 B2
9174037 Schutz et al. Nov 2015 B2
9179901 Young et al. Nov 2015 B2
9180248 Moberg et al. Nov 2015 B2
9474888 Wiley et al. Oct 2016 B2
9579496 Evans et al. Feb 2017 B2
9987467 Jochum Jun 2018 B2
10207095 Barron et al. Feb 2019 B2
10272236 Davey Apr 2019 B2
20010041870 Gillis et al. Nov 2001 A1
20010056266 Tallarida et al. Dec 2001 A1
20030023208 Osypka et al. Jan 2003 A1
20030181878 Tallarida et al. Sep 2003 A1
20040054352 Adams et al. Mar 2004 A1
20040073196 Adams et al. Apr 2004 A1
20040199129 DiMatteo Oct 2004 A1
20040204692 Eliasen Oct 2004 A1
20040254536 Conlon et al. Dec 2004 A1
20040254537 Conlon et al. Dec 2004 A1
20050075614 Bunodiere et al. Apr 2005 A1
20050113806 De Carvalho et al. May 2005 A1
20050131352 Conlon et al. Jun 2005 A1
20050148956 Conlon et al. Jul 2005 A1
20050148957 Girard et al. Jul 2005 A1
20050171502 Daly et al. Aug 2005 A1
20050209573 Brugger et al. Sep 2005 A1
20050256451 Adams et al. Nov 2005 A1
20050277899 Conlon et al. Dec 2005 A1
20060084929 Eliasen Apr 2006 A1
20060089619 Ginggen Apr 2006 A1
20060100592 Eliasen May 2006 A1
20060173424 Conlon Aug 2006 A1
20060178617 Adams et al. Aug 2006 A1
20060178647 Stats Aug 2006 A1
20060184142 Schon et al. Aug 2006 A1
20060217659 Patton Sep 2006 A1
20060217673 Schulze et al. Sep 2006 A1
20060224129 Beasley et al. Oct 2006 A1
20060247584 Sheetz et al. Nov 2006 A1
20060264898 Beasley et al. Nov 2006 A1
20060271012 Canaud et al. Nov 2006 A1
20070049806 Adams et al. Mar 2007 A1
20070073250 Schneiter Mar 2007 A1
20070078391 Wortley et al. Apr 2007 A1
20070078416 Eliasen Apr 2007 A1
20070083156 Muto et al. Apr 2007 A1
20070161958 Glenn Jul 2007 A1
20070179456 Glenn Aug 2007 A1
20070208313 Conlon et al. Sep 2007 A1
20070219510 Zinn et al. Sep 2007 A1
20070232997 Glenn Oct 2007 A1
20070233017 Zinn et al. Oct 2007 A1
20070233018 Bizup et al. Oct 2007 A1
20070255234 Haase Nov 2007 A1
20070270770 Bizup Nov 2007 A1
20070276344 Bizup et al. Nov 2007 A1
20070282308 Bell Dec 2007 A1
20080048855 Berger Feb 2008 A1
20080086075 Isik et al. Apr 2008 A1
20080108942 Blister et al. May 2008 A1
20080114308 di Palma et al. May 2008 A1
20080132946 Mueller Jun 2008 A1
20080208236 Hobbs et al. Aug 2008 A1
20080281279 Hoendervoogt et al. Nov 2008 A1
20080319399 Schweikert et al. Dec 2008 A1
20080319405 Bizup Dec 2008 A1
20090024024 Zinn Jan 2009 A1
20090024098 Bizup et al. Jan 2009 A1
20090105688 McIntyre et al. Apr 2009 A1
20090118683 Hanson et al. May 2009 A1
20090156928 Evans et al. Jun 2009 A1
20090192467 Hansen et al. Jul 2009 A1
20090204074 Powers et al. Aug 2009 A1
20090221976 Linden Sep 2009 A1
20090259164 Pages et al. Oct 2009 A1
20100042073 Oster et al. Feb 2010 A1
20100121283 Hamatake et al. May 2010 A1
20100298684 Leach et al. Nov 2010 A1
20110118677 Wiley May 2011 A1
20110257577 Lane et al. Oct 2011 A1
20110264058 Linden et al. Oct 2011 A1
20110319728 Petisce et al. Dec 2011 A1
20120172711 Kerr et al. Jul 2012 A1
20120283518 Hart Nov 2012 A1
20130030348 Lauer Jan 2013 A1
20130150767 Tsyrulnykov et al. Jun 2013 A1
20130150811 Horgan Jun 2013 A1
20150190622 Saab Jul 2015 A1
20150196704 Adler Jul 2015 A1
20150250933 Kerkhoffs et al. Sep 2015 A1
20150258322 Young et al. Sep 2015 A1
20150265280 Blatter et al. Sep 2015 A1
20150273201 Tallarida et al. Oct 2015 A1
20150290446 Wiley et al. Oct 2015 A1
20150306300 Phillips et al. Oct 2015 A1
20150327844 Hong et al. Nov 2015 A1
20160001055 Bourne et al. Jan 2016 A1
20180078751 Fedor et al. Mar 2018 A1
20190232035 Fedor et al. Aug 2019 A1
Foreign Referenced Citations (64)
Number Date Country
1261698 Sep 1989 CA
2318089 Jul 1999 CA
2551680 Jul 2005 CA
102271737 Dec 2011 CN
0229729 Jul 1987 EP
0366814 May 1990 EP
1056506 Dec 2000 EP
2948121 Nov 2017 EP
H05-506591 Sep 1993 JP
H07-148206 Jun 1995 JP
H08-501008 Feb 1996 JP
2008-531226 Aug 2008 JP
1991012838 Sep 1991 WO
1993005730 Apr 1993 WO
1994005246 Mar 1994 WO
WO 9405246 Mar 1994 WO
9625196 Aug 1996 WO
1996029112 Sep 1996 WO
1997001370 Jan 1997 WO
1997006845 Feb 1997 WO
1998017337 Apr 1998 WO
1999034859 Jul 1999 WO
1999042166 Aug 1999 WO
2000033901 Jun 2000 WO
2000044424 Aug 2000 WO
2000053245 Sep 2000 WO
2001026713 Apr 2001 WO
0180926 Nov 2001 WO
2002038460 May 2002 WO
2002066595 Aug 2002 WO
2003066126 Aug 2003 WO
2004004800 Jan 2004 WO
2004071555 Aug 2004 WO
2004091434 Oct 2004 WO
2004093970 Nov 2004 WO
2005068009 Jul 2005 WO
2006064753 Jun 2006 WO
2006078915 Jul 2006 WO
2006096686 Sep 2006 WO
2006116438 Nov 2006 WO
2006130133 Dec 2006 WO
2006134100 Dec 2006 WO
2007079024 Jul 2007 WO
2007082003 Jul 2007 WO
2007087460 Aug 2007 WO
2007092210 Aug 2007 WO
2007094898 Aug 2007 WO
2007098771 Sep 2007 WO
2007109164 Sep 2007 WO
2007126645 Nov 2007 WO
2007136538 Nov 2007 WO
2008048361 Apr 2008 WO
2008063226 May 2008 WO
2008140901 Nov 2008 WO
2008157763 Dec 2008 WO
2009002839 Dec 2008 WO
2009012385 Jan 2009 WO
2009035582 Mar 2009 WO
2009046439 Apr 2009 WO
2009108669 Sep 2009 WO
2012064881 May 2012 WO
2014017986 Jan 2014 WO
2014116810 Jul 2014 WO
2015179862 Nov 2015 WO
Non-Patent Literature Citations (15)
Entry
PCT/US2014/012721 filed Jan. 23, 2014 International Search Report and Written Opinion dated Apr. 14, 2014.
Canaud, B. et. al. “Dialock: a new vascular access device for extracorporeal renal replacement therapy. Preliminary clinical results” (Mar. 1999).
Goldstein, D. J. et. al. “Implantable Left Ventricular Assist Devices” (Nov. 19, 1998).
Moran, J. E. “Subcutaneous Vascular Access Devices” (Nov. 2001).
Rosenblatt, M. et. al. “Efficacy and Safety Results with the LifeSite Hemodialysis Access System versus the Tesio-Cath Hemodialysis Catheter at 12 Months” (Mar. 2006).
Sandhu, J. Dialysis Ports: A New Totally Implantable Option for Hemodialysis Access (Jun. 2002).
CN 201480005902.2 filed Jul. 23, 2015 Office Action dated Jul. 19, 2016.
EP 14743846.9 filed Aug. 12, 2015 Extended European Search Report dated Oct. 10, 2016.
CN 201480005902.2 filed Jul. 23, 2015 Office Action dated Jan. 20, 2016.
CN 201480005902.2 filed Jul. 23, 2015 Office Action dated May 12, 2017.
EP 14743846.9 filed Aug. 12, 2015 Intent to Grant dated Jun. 26, 2017.
JP 2015-555266 filed Jul. 22, 2015 Office Action dated Oct. 12, 2017.
PCT/US2017/061179 filed Nov. 10, 2017 International Search Report and Written Opinion dated Jan. 22, 2018.
JP 2015-555266 filed Jul. 22, 2015 Office Action dated May 2, 2018.
U.S. Appl. No. 29/616,511, filed Sep. 6, 2017 Notice of Allowance dated Aug. 8, 2019.
Related Publications (1)
Number Date Country
20140207086 A1 Jul 2014 US
Provisional Applications (1)
Number Date Country
61755913 Jan 2013 US